Calming exercises can help tame anxiety, but a creative life is a cure-all according to author Martha Beck: “Anxiety can’t ...

Mind Medicine (MNMD) announced that the first patient has been dosed in Panorama, its second Phase 3 study evaluating MM120 ...

MindMed has dosed the first subject in the Phase III Panorama study of MM120 ODT for the treatment of generalised anxiety ...

In this week’s “Psychedelic,” The Fly’s recurring series focused on psychedelic stock news, The Fly looks back on study results, an analyst ...

Antidepressants, such as Prozac, are already used to treat the condition but Canadian and Italian scientists set out to ...

The MM120 ODT Phase 3 clinical development program also includes the Voyage study for GAD and the Emerge study for major depressive disorder (MDD). The U.S. Food and Drug Administration has granted ...

Inc. (NASDAQ: MNMD), (the "Company" or "MindMed"), a late-stage clinical biopharmaceutical company developing novel product ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under trial conditions, although there is limited data on long-term usage.

Glutamatergic medications are linked to significant symptom improvement in obsessive-compulsive and related disorders, a new ...

A new Cochrane review confirms that antidepressants effectively reduce symptoms of generalized anxiety disorder (GAD) under ...

Inc. stock despite strong Phase 2b data. Click for my updated look at MNMD stock and its market opportunities.